ClinicalTrials.gg
CompletedNCT06183216Updated Jan 28, 2026

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

A Phase 1 interventional study of Sinovac PCV13 and PREVNAR 13 in Pneumococcal Infectious Disease, sponsored by Sinovac Research and Development Co., Ltd.. Completed at 1 site in China. Open to participants aged 6 Weeks to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Sinovac Research and Development Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
6 Weeks to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Sinovac Biotech Co., Ltd.

Enrollment
11th of 12
140 · median 403
Started
2024
with 3 others
Phase 1
5 of 13
1 open now
Registered
6th of 13
by date

Among the 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2024, is one of 5 in phase 1, and was the 6th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

3 of the 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 6 Weeks to 5 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV13. The trial is a randomized, double blinded, positive controlled study.

Read the detailed description

A phase Ⅰb clinical trial of the study of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted in Chinese children aged 2 months (42-89 days) and 2 to 5 years. The trial is an randomized, double-blind and active controlled study. The objective of this study is to evaluate the safety and immunogenicity of PCV13 manufactured by Sinovac Life Science Co., Ltd. The active control vaccine is the PREVNAR 13 manufactured by Pfizer Inc. A total of 140 participants will be enrolled, including 70 children aged 2-5 years old, and 70 infants aged 2 months (42-89 days). Participants will be randomized to receive either Sinovac PCV13 or Pfizer PCV13 in a 1:1 ratio. Children aged 2-5 years old will receive 1 dose; Infants aged 2 months will receive 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months.

03

Conditions studied

  • Pneumococcal Infectious Disease
04

Who can participate

Ages eligible
6 Weeks to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy infants aged 2 months (42-89 days); Healthy children aged 2-5 years.
  2. Proven vaccination certificate, birth certificate and legal identification documents
  3. The participants' guardians can understand and voluntarily sign the form.
  4. Participants and their guardians can obey requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Received any pneumococcal vaccine prior to enrollment.
  2. History of culture confirmed bacterial pneumonia or invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae.
  3. History of allergy to the vaccine or vaccine components, including pneumococcal polysaccharide for each serotype, diphtheria CRM197, aluminum phosphate, succinic acid, polysorbate 80 and sodium chloride; or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and asthma.
  4. History of dystocia, asphyxia rescue, nervous system damage at birth (only applicable to infants aged 2 months (42-89 days))
  5. Congenital malformations or developmental disorders, genetic defects, severe malnutrition, asthma etc.
  6. disease (such as systemic lupus erythematosus) or immunodeficiency/ (such as , organ transplantation)
  7. Severe cardiovascular diseases, such as diabetes, liver diseases, kidney diseases, malignant tumors.
  8. Family history of mental illness, severe neurological disease (epilepsy or convulsions) or mental illness.
  9. History of thyroidectomy, asplenia, functional asplenia; and asplenia or splenectomy resulting from any condition.
  10. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal ), history of obvious bleeding or bruising after intramuscular injection or venipuncture.
  11. Infants 2 months of age (42-89 days) prior to enrollment/children 2 to 5 years of age 6 months prior to enrollment had been treated with , other immunosuppressive agents (excluding corticosteroid spray therapy for allergic rhinitis, superficial corticosteroid therapy for acute non-concurrent dermatitis) or cytotoxic therapy for ≥14 days
  12. Infants 2 months of age (42-89 days) prior to enrollment/children 2 to 5 years of age 3 months prior to enrollment received blood products within the past 3 months (excluding immunoglobulin within 1 month).
  13. Receipt of other drugs in the past 60 days or have the plan to participate in other clinical trials during this study.
  14. Receipt of attenuated in the past 14 days.
  15. Receipt of inactivated or subunit vaccines in the past 7 days.
  16. Acute diseases or acute exacerbation of chronic diseases in the past 7 days.
  17. Axillary temperature ≥37.3 °C.
  18. According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Infants aged 2 months in experimental group

    35 participants aged 2 months will be randomized to receive Sinovac PCV13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months.

    Biological: Sinovac PCV13

  • Active comparator
    Infants aged 2 months in control group

    35 participants aged 2 months will be randomized to receive PREVNAR 13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months.

    Biological: PREVNAR 13

  • Experimental
    Children aged 2-5 years in experimental group

    35 children aged 2-5 years will be randomized to receive Sinovac PCV13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old.

    Biological: Sinovac PCV13

  • Active comparator
    Children aged 2-5 years in control group

    35 children aged 2-5 years will be randomized to receive PREVNAR 13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old.

    Biological: PREVNAR 13

Interventions

  • BiologicalSinovac PCV13

    0.5 mL dose of Sinovac PCV13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.

  • BiologicalPREVNAR 13

    0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse reactions

    Incidence of adverse reactions within 30 days after each dose

    Time frame: 0-30 days after each dose

Secondary outcomes

  1. Incidence of adverse reactions

    Incidence of adverse reactions within 7 days after each dose

    Time frame: 0-7 days after each dose

  2. Incidence of SAE

    Incidence of SAE during the period of safety monitoring

    Time frame: 6 months after vaccination for children aged 2-5 years; 1 month after completion of booster vaccination for infants aged 2 months.

  3. IgG concentration ≥0.35μg/mL for infants aged 2 months

    The proportion of participants achieving an IgG concentration ≥0.35μg/mL (seropositivity rate) for each serotype 30 days after primary/booster immunization.

    Time frame: 30 days after primary/booster immunization

  4. IgG concentration ≥1.0μg/mL for infants aged 2 months

    The proportion of participants achieving an IgG concentration ≥1.0μg/mL for each serotype 30 days after primary/booster immunization.

    Time frame: 30 days after primary/booster immunization

  5. GMCs for infants aged 2 months

    GMCs for each serotype 30 days after primary/booster immunization

    Time frame: 30 days after primary/booster immunization

  6. GMIs for infants aged 2 months

    GMIs (GMC increase folds) for each serotype 30 days after primary/booster immunization

    Time frame: 30 days after primary/booster immunization

  7. IgG concentration ≥0.35μg/mL for children aged 2-5 years

    The proportion of participants achieving an IgG concentration ≥0.35μg/mL (seropositivity rate) for each serotype 30 days after vaccination.

    Time frame: 30 days after vaccination

  8. IgG concentration ≥1.0μg/mL for children aged 2-5 years

    The proportion of participants achieving an IgG concentration ≥1.0μg/mL for each serotype 30 days after vaccination.

    Time frame: 30 days after vaccination

  9. GMCs for children aged 2-5 years

    GMCs for each serotype 30 days after vaccination

    Time frame: 30 days after vaccination

  10. GMIs for children aged 2-5 years

    GMIs (GMC increase folds) for each serotype 30 days after vaccination

    Time frame: 30 days after vaccination

07

Study locations

1 site
  • Binchuan County Center for Diseases Control and Prevention
    Dali, Yunnan 671600, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Mar 2025, 14 months.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 14 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 27, 2023
StartActual
Jan 4, 2024
Primary completionActual
Mar 26, 2025
CompletionActual
Mar 26, 2025
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06183216
Responsible party
Sponsor
First posted
Dec 27, 2023
Start date
Jan 4, 2024
Primary completion
Mar 26, 2025
Completion
Mar 26, 2025
Last update
Jan 28, 2026

Study contacts

Yan Zheng
principal investigator · Yunnan Provincial Center for Disease Prevention and Control

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion